GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

The CDC plans to publish clinical considerations that outline the chronic medical conditions and other risk factors for severe RSV disease to be used under this recommendation.

Key Takeaways High-risk adults as young as 50 are now eligible for the RSV vaccineThe update follows advice from now-deposed members of a federal vaccine panelRSV can be dangerous for older adults ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to high-risk adults as young as 50, too.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The CDC published a new recommendation this week calling for some adults ages 50 to 59 to get vaccinated for respiratory syncytial virus (RSV).

RSV vaccine access expanded to some people in their 50s, according to CDC website The decision appears on a CDC webpage but wasn’t on the agency’s official adult immunization schedule.